The case for & against
Bull & Bear analysis
Bearish
American Shared Hospital Services (NYSE: AMS) specializes in advanced radiation therapy solutions, operating primarily through partnerships with health systems to facilitate cancer care. The company has transitioned from a medical equipment leasing model to a more patient-centric service model, enhancing its market position and aligning with rising demand for efficient cancer treatment services. AMS is strategically expanding its footprint in the U.S. and internationally, particularly in Latin America, with targeted acquisitions and facility openings.
Bull says
- ↑Q1 2025 revenue rose 17% YoY to $6.1M; Puebla center up 263%.
- ↑Direct patient care revenue climbed 23.7% to $15.5M, now 63% of total.
- ↑Pivot to patient-centric services expected to boost margins and resilience.
- ↑Mexico expansion with sole Esprit gamma knife addresses 130M population.
- ↑Strong QS score and 1.27% dividend yield signal financial quality.
- ↑Gamma Knife segment revenue grew 16% to $2.1M, showing stable demand.
Bear says
- ↓Q4 2025 net loss $1.6M and adjusted EBITDA fell to $868K.
- ↓Leasing revenue dropped 33.9% on lower PBRT volumes, hitting stability.
- ↓Cash down to $3.7M from $11M in 2024; debt pressures persist.
- ↓Negative earnings yield and low profitability score reflect weak returns.
- ↓Q4 revenue declined 14.8% to $7.7M; treatment volumes volatile.
- ↓Market cap ~$13M with thin trading underpins investor confidence risk.
Earnings Call · Q1 2025 · Mgmt. Guidance
Updated 07-11-2026neutral
Transcript signals
Bull points
- My confidence and enthusiasm for our business continues to grow, and I'm excited to lead the company into our next phase of growth with our strong management team.
- I am enthused by the growth we are seeing in the overall business, and even more so with our business development initiatives we have in motion. At the Rhode Island centers, our upgraded CT simulators used in the patient treatment planning and software enhancements for improved efficiency and patient care are in place, and we are well positioned to show positive results for the long term.
- Our international business segment continues to represent a large growth opportunity where we are expecting continued momentum.
Bear points
- Treatment volumes in cancer care can tend to ebb and flow from time to time due to changes in diagnosis mix, patient staging, and referring physician consults, and can result in lower treatment volumes that we experienced in the first quarter.
- Gamma Knife revenue declined 18% to $2.1 million for Q1 2025 compared to $2.6 million Q1 2024. The number of Gamma Knife procedures in Q1 2025 was 208, a 24% decrease from the 273 procedures in 2024. The decline was primarily due to the expiration of two contracts in December 2024 and February 2025, and downtime to upgrade a third customer to a new electa S3.
- Revenue from proton beam radiation therapy decreased 38% to 1.6 million in Q1 2025, compared to 2.7 million in Q1 2024. Total proton therapy fractions for Q1 2025 were 831, a 35% decrease from the 1,276 fractions in Q1 2024. This decline was primarily due to lower volumes.
Read full transcript analysis ›